Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 8
- Countries
- 0
Exclusivity
Patents and exclusivities
8| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10072013 | UKONIQumbralisib tosylate | use | Jul 2033 |
| 10570142 | UKONIQumbralisib tosylate | substance, product | Jul 2033 |
| 10981919 | UKONIQumbralisib tosylate | use | Jul 2033 |
| 9150579 | UKONIQumbralisib tosylate | substance, product | Jul 2033 |
| 9669033 | UKONIQumbralisib tosylate | use | Jul 2033 |
| 10414773 | UKONIQumbralisib tosylate | substance, product | May 2035 |
| 10947244 | UKONIQumbralisib tosylate | use | May 2035 |
| 9969740 | UKONIQumbralisib tosylate | substance, product | May 2035 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| BRIUMVI | ublituximab | injection, solution, concentrate, intravenous | 73150-150BLA |
Compare
Other companies listing ublituximab
- Samsung Biologics Co., Ltd.2 sites · 57 NDC
Enquiry
Common questions
- Is TG Therapeutics, Inc. FDA approved?
- TG Therapeutics, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does TG Therapeutics, Inc. make?
- 1 product is listed under TG Therapeutics, Inc. in the openFDA NDC Directory, most often as injection, solution, concentrate. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.